31 Supported by research
Targeting mitochondria to increase their function can overcome the neurodegenerative process in peripheral neuropathy.
"if you target the mitochondria to drive up its function, you can overcome the degenerative process." (said at 0:00:00)
Preclinical models of peripheral neuropathy (such as diabetic, chemotherapy-induced, and HIV-associated neuropathies) demonstrate that enhancing mitochondrial bioenergetics and calcium homeostasis (e.g., via muscarinic receptor antagonism or TRPM3 activation) can promote axonal repair and overcome neurodegenerative phenotypes. However, while these strategies show promising disease-modifying potential in cellular and animal models, evidence in human clinical trials remains preliminary.
- supports: Muscarinic Receptor Antagonism and TRPM3 Activation as Stimulators of Mitochondrial Functi… (International journal of molecular sciences 2025) · cited 3x in the literature
"Recent findings have demonstrated that antagonism of the muscarinic acetylcholine type 1 receptor (M 1 R) promotes restoration of mitochondrial function and axon repair in various neuropathies, including DSPN, chemotherapy-induced peripheral neuropathy (CIPN) and HIV-associated neuropathy." (abstract, results, passage verified)
pubmedfull study (doi) - context: Diabetic Peripheral Neuropathy: Mechanisms and Emerging Therapies. (Biology 2026) · cited 2x in the literature
"Emerging therapeutic strategies, including antioxidants, anti-inflammatory agents, modulators of mitochondrial function, amyloid oligomer modulators, neurotrophic enhancers, and regenerative approaches such as stem cells and gene-based therapies, offer potential to modify disease progression. The strength of evidence across these methods varies, ranging from mechanistic and animal studies to early human research and, in some cases, randomized clinical trials. Therefore, although several candidates show potential to alter the disease, few have demonstrated consistent benefits on objective measures of nerve structure or function in large clinical trials." (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 20 million individuals in the United States suffer from peripheral neuropathy.
"Estimated that here in America, about 20 million individuals suffer from problems related to the peripheral nerves or peripheral neuropathy." (said at 0:00:50)
The host's statement that an estimated 20 million individuals in the United States suffer from peripheral neuropathy or peripheral nerve problems is well supported by published biomedical literature and public health estimates (such as those from the National Institute of Neurological Disorders and Stroke). Multiple peer-reviewed studies explicitly cite that peripheral neuropathy affects approximately 20 million people in the United States.
Diabetic neuropathy occurs in more than 50% of diabetics at some point during their lifetime.
"You've probably heard of diabetic neuropathy, and that occurs in more than 50% of diabetics at some point during their lifetimes." (said at 0:01:06)
Diabetic neuropathy (most commonly diabetic peripheral neuropathy) is widely recognized as one of the most frequent microvascular complications of diabetes. Epidemiological reviews and clinical consensus consistently document that the lifetime prevalence of diabetic peripheral neuropathy reaches approximately 50% or more (>50%) among individuals with diabetes over the course of their disease.
- supports: Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropat… (Diabetes & metabolism journal 2023) · cited 83x in the literature
"Diabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes. The lifetime prevalence of DPN is thought to be >50%, and 15%-25% of patients with diabetes experience neuropathic pain, referred to as "painful DPN."" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Diabetic Neuropathy: A Guide to Pain Management. (Current pain and headache reports 2024) · cited 13x in the literature
"Diabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Diabetic Peripheral Neuropathy: Current Epidemiology, Diagnostic Advances, Biomarkers, and… (Journal of diabetes research 2026) · cited 3x in the literature
"Diabetic peripheral neuropathy (DPN) is one of the most common and disabling complications of diabetes mellitus (DM), affecting up to 50% of patients during the course of their disease." (abstract, results, passage verified)
pubmedfull study (doi)
Up to one-third of chemotherapy patients develop damage to their peripheral nerves.
"Up to a third of chemotherapy patients will have damage to their nerves." (said at 0:01:16)
Published systematic reviews and meta-analyses show that chemotherapy-induced peripheral neuropathy (CIPN) affects a large proportion of chemotherapy patients. A landmark meta-analysis of 31 studies (4,179 patients) by Seretny et al. found that CIPN prevalence is approximately 68% in the first month following chemotherapy, 60% at 3 months, and approximately 30% (one-third) persists at 6 months or longer. More recent global meta-analyses report overall incidence and prevalence rates between 50% and 56%, confirming that at least one-third (and often more during active treatment) of patients receiving neurotoxic chemotherapy regimens experience peripheral nerve damage.
- supports: Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A sys… (Pain 2014) · cited 1571x in the literature
"CIPN prevalence was 68.1% (57.7-78.4) when measured in the first month after chemotherapy, 60.0% (36.4-81.6) at 3months and 30.0% (6.4-53.5) at 6months or more." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The global prevalence of peripheral neuropathy following chemotherapy in cancer patients: … (Orphanet journal of rare diseases 2026)
"Following the assessment of 49 eligible studies (n:33,667 participants), the overall CIPN prevalence was reported 51.9% (95% CI: 45-58.7)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer … (Frontiers in neurology 2026) · cited 4x in the literature
"23 studies involving a sample size of 15,090 cases were included, and 16 influencing factors were identified. The incidence of CIPN in cancer patients was 56% (95% CI: 46-66%, p < 0.01)." (abstract, results, passage verified)
pubmedfull study (doi)
Platinum-based chemotherapies have a higher incidence of nerve damage compared to other chemotherapy types.
"It's certainly higher in certain types of chemotherapy like the platinum-based chemotherapies." (said at 0:01:25)
Platinum-based chemotherapies (such as cisplatin, oxaliplatin, and carboplatin) are well-established as having among the highest rates and severities of chemotherapy-induced peripheral neuropathy (CIPN) compared to most other chemotherapy classes. Systematic reviews and clinical reviews identify platinum compounds, along with taxanes, vinca alkaloids, and proteasome inhibitors, as the primary neurotoxic agents in cancer treatment, with platinum agents like oxaliplatin producing some of the highest cumulative rates of neurotoxicity.
- supports: Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. (Oncology and therapy 2021) · cited 296x in the literature
"The primary classes of chemotherapeutic agents associated with CIPN are platinum-based drugs, taxanes, vinca alkaloids, bortezomib and thalidomide. Platinum agents are the most neurotoxic, with oxaliplatin causing the highest prevalence of CIPN." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neurop… (Regional anesthesia and pain medicine 2025) · cited 41x in the literature
"Subgroup analysis revealed that patients treated with platinum-based agents and taxanes had the highest prevalence of chronic moderate-to-severe CIPN or painful CIPN (44.47% and 55.68%, respectively)" (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 25% of all peripheral neuropathies are idiopathic.
"around a quarter of all peripheral neuropathies are what we call idiopathic. Means that we don't fully have a readily available explanation in terms of what's causing that peripheral neuropathy." (said at 0:01:45)
A systematic epidemiological review of population-based studies evaluating chronic polyneuropathy found that despite diagnostic workups, a substantial proportion (20% to 30%, centering around 25%) of cases remains idiopathic (without an identifiable underlying cause).
Around 30 million people in the United States suffer from some form of peripheral neuropathy.
"In the US, around 30 million people suffering from some form of peripheral neuropathy." (said at 0:06:35)
Epidemiological literature on the burden of peripheral neuropathy in the United States commonly estimates that 20 to 30 million Americans are affected by some form of peripheral neuropathy across various etiologies (including diabetic neuropathy, chemotherapy-induced neuropathy, toxic/metabolic causes, and idiopathic forms). Published reviews document that peripheral neuropathies affect over 20 million individuals in the US, making the speaker's figure of 'around 30 million' an accurate approximation of the broad epidemiological range.
Diabetes is the leading cause of peripheral neuropathy in the United States.
"So, the common causes of neuropathy in the US are No. 1 is diabetes." (said at 0:06:45)
Epidemiological literature and clinical reviews consistently identify diabetes mellitus as the leading cause of peripheral neuropathy in the United States and other Western nations, accounting for more than 50% of all diagnosed peripheral neuropathy cases.
- supports: Diabetic neuropathy. (Continuum (Minneapolis, Minn.) 2012) · cited 56x in the literature
"Diabetes is the most common cause of peripheral neuropathy in the world. More than half of patients with diabetes have neuropathy, and half of patients with neuropathy have diabetes." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Peripheral Neuropathy: A Review. (JAMA 2026) · cited 49x in the literature
"Diabetic neuropathy, which is often associated with both sensory symptoms, such as pain, tingling, or numbness; mild weakness; and autonomic symptoms, such as orthostatic hypotension, accounts for more than 50% of peripheral neuropathy in Western populations." (abstract, results, passage verified)
pubmedfull study (doi)
Over the last 20 to 30 years in the United States, the rate of progression of diabetic neuropathy has slowed.
"We do know that over the last 20 to 30 years in the US the rate of the progression of neuropathy has been slowed." (said at 0:08:40)
Longitudinal cohort and national surveillance data in the United States demonstrate a secular decline in the progression and rate of diabetic neuropathy and its end-stage sequelae over the past several decades. Findings from the prospective Pittsburgh Epidemiology of Diabetes Complications Study revealed a significant decreasing trend in diabetic neuropathy across successive diagnosis cohorts evaluated at 20- and 25-year diabetes durations (P < 0.05). In addition, nationwide surveillance from 1990 to 2010 documented a 51.4% reduction in lower-extremity amputations among adults with diabetes, reflecting substantial deceleration in the severe progression of neuropathic and vascular disease.
- supports: The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology … (Diabetes 2006) · cited 493x in the literature
"There was a decreasing trend by diagnosis year for mortality, renal failure, and neuropathy across all time intervals (P < 0.05), with the 1950-1959 cohort having a fivefold higher mortality at 25 years than the 1970s' cohorts." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Changes in diabetes-related complications in the United States, 1990-2010. (The New England journal of medicine 2014) · cited 1746x in the literature
"Rates of all five complications declined between 1990 and 2010, with the largest relative declines in acute myocardial infarction (-67.8%; 95% confidence interval [CI], -76.2 to -59.3) and death from hyperglycemic crisis (-64.4%; 95% CI, -68.0 to -60.9), followed by stroke and amputations, which each declined by approximately half (-52.7% and -51.4%, respectively)" (abstract, results, passage verified)
pubmedfull study (doi)
Visit-to-visit blood sugar variability is associated with an increased risk of dementia.
"a study that I just read last night in the Journal of Neurology talked about risk of dementia with just variability of blood sugar from one office visit to the next." (said at 0:10:45)
Observational cohort studies and meta-analyses support the claim that visit-to-visit variability in blood glucose or HbA1c is associated with an increased risk of cognitive impairment, brain neurodegenerative changes, and Alzheimer's disease. A 2024 study published in the journal Neurology demonstrated that intraindividual visit-to-visit fasting glucose variability was significantly associated with neuroimaging markers of amyloid accumulation, white matter hyperintensities, brain atrophy, and cognitive dysfunction. Larger population-based cohort studies have similarly identified visit-to-visit fasting plasma glucose and HbA1c fluctuations as independent predictors of incident Alzheimer's disease.
- supports: Visit-to-Visit Variations in Fasting Plasma Glucose and HbA 1c Associated With an Increase… (Diabetes care 2017) · cited 82x in the literature
"After adjustment for sociodemographic factors, lifestyle behaviors, diabetes-related variables, FPG and HbA 1c , drug-related variables, and comorbidities, both FPG CV and HbA 1c CV were found to be significant predictors of AD, with corresponding hazard ratios of 1.27 (95% CI 1.06-1.52) for the third tertile in FPG CV and 1.32 (95% CI 1.11-1.58) for the third tertile in HbA 1c CV." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Association of Glycemic Variability With Imaging Markers of Vascular Burden, β-Amyloid, Br… (Neurology 2024) · cited 13x in the literature
"We defined GV as the intraindividual visit-to-visit variability in FG levels... Our findings suggest that increased GV is related to vascular and Alzheimer risk factors and neurodegenerative markers, which in turn leads to subsequent cognitive impairment. Furthermore, GV can be considered a potentially modifiable risk factor for dementia prevention." (abstract, methods and conclusions)
pubmedfull study (doi)
For certain chemotherapeutic agents, 80% to 90% of patients are expected to develop peripheral neuropathy.
"Some of them it's 80 or 90% of patients would be expected to get neuropathy." (said at 0:12:12)
Clinical and epidemiological research confirms that for specific neurotoxic chemotherapeutic agents—notably platinum compounds such as oxaliplatin and certain taxanes—the overall incidence of chemotherapy-induced peripheral neuropathy (CIPN) can reach 80% to 90% or higher during active treatment. In large observational cohorts and systematic reviews evaluating neurotoxic regimens, acute or cumulative sensory neuropathy of any grade is documented in up to 90% or more of patients receiving these agents.
- context: Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A sys… (Pain 2014) · cited 1571x in the literature
"CIPN prevalence was 68.1% (57.7-78.4) when measured in the first month after chemotherapy, 60.0% (36.4-81.6) at 3months and 30.0% (6.4-53.5) at 6months or more. Different chemotherapy drugs were associated with differences in CIPN prevalence" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. (Oncology and therapy 2021) · cited 296x in the literature
"The primary classes of chemotherapeutic agents associated with CIPN are platinum-based drugs, taxanes, vinca alkaloids, bortezomib and thalidomide. Platinum agents are the most neurotoxic, with oxaliplatin causing the highest prevalence of CIPN." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Incidence and Risk Factors Associated with Platinum Derivative Chemotherapy-Induced Periph… (Asian Pacific journal of cancer prevention : APJCP 2026)
"Among 3,140 patients, 16,878 events were evaluated, with 7,187 (42.58%), 5,514 (32.67%), and 4,177 (24.75%) patients treated with cisplatin, carboplatin, or oxaliplatin, respectively. The incidence of any event of PSPN was 98.85%" (abstract, results, passage verified)
pubmedfull study (doi)
Certain HIV therapeutics impair mitochondrial function.
"some of the HIV therapeutics actually hit mitochondrial function, which is one of our targets with our drug that we'll hear about later." (said at 0:15:33)
It is well-established that certain antiretroviral therapeutics, particularly nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine, stavudine, and didanosine, impair mitochondrial function. The classical mechanism involves the inhibition of human mitochondrial DNA polymerase-gamma (Pol-γ), leading to mitochondrial DNA depletion, respiratory chain dysfunction, and clinical complications such as peripheral neuropathy, myopathy, lipoatrophy, and lactic acidosis.
Unmyelinated nerve fibers require local ATP production along their entire length for conduction, whereas myelinated fibers produce ATP primarily at the nodes of Ranvier.
"many of them you have unmyelinated fibers, which means the nerve conduction has to go all the way along the nerve with local production of ATP along the whole length of the nerve as opposed to a myelinated nerve where you have energy production primarily at the nodes of Ranvier." (said at 0:17:35)
The speaker's statement accurately reflects basic axonal physiology and bioenergetics. In unmyelinated axons, continuous impulse propagation requires ion pumping (Na+/K+-ATPase) and ATP production uniformly distributed along the entire length of the fiber. In contrast, myelinated axons employ saltatory conduction, confining action potential regeneration and the highest metabolic demands primarily to the unmyelinated gaps (nodes of Ranvier), where axonal mitochondria are preferentially clustered.
Excess glucose entering neurons shifts their metabolism toward glycolysis, leading to downregulation and loss of mitochondria.
"Its metabolism is affected by all this sugar that's coming into the neuron. And as a result, it becomes more reliant upon glycolysis. And so, it actually switches off its mitochondria as almost as an inbuilt system. And what this means though in terms of neurons, especially the nerve endings, which have very high energy requirements, you actually see a loss of mitochondria, and it's been shown in human tissue as well as animal studies." (said at 0:18:25)
Nutrient excess and elevated intracellular glucose concentrations in sensory neurons trigger metabolic maladaptation via nutrient-sensing pathways (such as AMPK/SIRT/PGC-1α), causing suppression of mitochondrial oxidative phosphorylation and a shift toward glycolysis. This downregulation of mitochondrial respiratory chain gene expression, function, and distal energetic capacity in energy-demanding nerve endings has been demonstrated in both animal models of diabetes and human tissue biopsies.
- supports: Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events… (Current diabetes reports 2015) · cited 163x in the literature
"Diabetes (type 1 or type 2) invokes an elevation of intracellular glucose concentration simultaneously with impaired growth factor support by insulin, and this dual alteration triggers a maladaptation in metabolism of adult sensory neurons. The energy sensing pathway comprising the AMP-activated protein kinase (AMPK)/sirtuin (SIRT)/peroxisome proliferator-activated receptor-γ coactivator α (PGC-1α) signaling axis is the target of these damaging changes in nutrient levels, e.g., induction of nutrient stress, and loss of insulin-dependent growth factor support and instigates an aberrant metabolic phenotype characterized by a suppression of mitochondrial oxidative phosphorylation and shift to anaerobic glycolysis. There is discussion of how this loss of mitochondrial function and transition to overreliance on glycolysis contributes to the diminishment of collateral sprouting and axon regeneration in diabetic neuropathy in the context of the highly energy-consuming nerve growth cone." (abstract, passage verified)
pubmedfull study (doi) - supports: Insulin prevents aberrant mitochondrial phenotype in sensory neurons of type 1 diabetic ra… (Experimental neurology 2017) · cited 31x in the literature
"Down-regulation of mitochondrial gene expression and function has been reported in both human tissues and in dorsal root ganglia (DRG) from animal models of type 1 and type 2 diabetes." (abstract, introduction, passage verified)
pubmedfull study (doi)
Pain affects approximately one-third to one-half of patients with diabetic neuropathy.
"the pain had always been there. It impacts about a third to a half of the patients with neuropathy." (said at 0:21:55)
Published epidemiological literature and systematic reviews confirm that painful diabetic peripheral neuropathy (PDPN) affects approximately one-third to one-half of individuals with diabetic peripheral neuropathy. A 2025 systematic review and meta-analysis of 41 observational studies found a pooled global prevalence of painful diabetic peripheral neuropathy of 46.7% (95% CI, 41.8–51.7%) among patients with diabetic neuropathy.
Pregabalin was approved by the FDA for the treatment of diabetic neuropathy pain.
"Pregabalin was approved, the son of gabapentin was approved for use in diabetic neuropathy, and suddenly there was a route that you could follow." (said at 0:23:25)
Pregabalin (Lyrica) received FDA approval specifically for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), becoming one of the first oral medications approved for this indication and serving as a guideline-recommended first-line therapy.
- supports: Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. (Clinical therapeutics 2018) · cited 490x in the literature
"Duloxetine and pregabalin remain first-line therapy for neuropathic pain in DPN in all 5 of the major published guidelines by the American Association of Clinical Endocrinologists, American Academy of Neurology, European Federation of Neurological Societies, National Institute of Clinical Excellence (United Kingdom), and the American Diabetes Association, and their use has been approved by the US Food and Drug Administration." (abstract, passage verified)
pubmedfull study (doi) - supports: Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelin… (Journal of pain research 2024) · cited 38x in the literature
"Four pharmacologic options are currently approved by the US Food and Drug Administration (FDA) to treat painful DPN. These include three oral medications (duloxetine, pregabalin, and tapentadol extended release) and one topical agent (capsaicin 8% topical system)." (abstract, passage verified)
pubmedfull study (doi)
There are no FDA-approved drugs in the United States to treat the underlying nerve degeneration and loss in diabetic neuropathy.
"Because nothing has ever been approved to treat diabetic neuropathy, the nerve degeneration and loss, there is no route." (said at 0:23:45)
The statement is accurate. While several medications (such as pregabalin, duloxetine, and tapentadol) are FDA-approved to manage symptoms and pain associated with diabetic peripheral neuropathy, there are currently no FDA-approved disease-modifying therapies aimed at slowing, stopping, or reversing the underlying nerve degeneration and structural loss.
Uric acid inhibits nitric oxide production.
"how uric acid inhibits nitric oxide, which interestingly is very important for the function of nerves, for the vascular uh supply to nerves" (said at 0:25:30)
Experimental in vitro and animal models demonstrate that elevated uric acid reduces nitric oxide (NO) production and bioavailability in vascular endothelial cells. Mechanistically, uric acid impairs endothelial nitric oxide synthase (eNOS) activity by inducing oxidative and endoplasmic reticulum stress, disrupting insulin-mediated PI3K/Akt/eNOS signaling, and increasing inhibitory phosphorylation of eNOS.
In the lens of the eye, aldose reductase converts glucose to sorbitol, which acts as an osmolyte, causing lens fibers to swell and burst to form cataracts.
"basically the you know, very crudely the glucose gets into the cells of the lens. They swell because they make sorbitol. I mean, the progression of aldose reductase from glucose to fructose includes an intermediate sorbitol that is a very strong osmolyte. And so, the so sorbitol accumulates in the lens, they swell, the lens fibers burst and you and you start getting cataracts with these accumulations." (said at 0:27:20)
The speaker accurately describes the classic polyol pathway (osmotic) mechanism of diabetic cataractogenesis. Under hyperglycemic conditions, aldose reductase reduces excess intracellular glucose into sorbitol. Because sorbitol is poorly permeable to cell membranes, it accumulates intracellularly and acts as an osmolyte, drawing water into the lens fibers. This osmotic swelling leads to cellular disruption, membrane damage, and lens opacification (cataract formation). While additional factors such as oxidative stress and advanced glycation end-products also contribute in human diabetic cataracts, the aldose reductase-mediated sorbitol osmotic swelling mechanism is well established.
Aldose reductase inhibitors effectively prevent cataractogenesis and treat complications of diabetes in rodent models.
"And aldose reductase inhibitors are perfect blockers of cataractogenesis. Um in fact, they cured most things in animals through the '60s and '70s and '80s. Um in all the animal models, they fixed pretty much everything." (said at 0:26:46)
Extensive preclinical literature from the 1960s through the 1980s and beyond demonstrates that aldose reductase inhibitors (ARIs, such as sorbinil) effectively block or reverse cataractogenesis and mitigate other diabetic complications (such as retinopathy, neuropathy, and nephropathy) in rodent and other animal models. In diabetic and galactosemic rodents, accumulation of sorbitol via the polyol pathway causes osmotic stress and tissue damage, which ARIs consistently prevented in laboratory models, despite subsequent challenges translating these robust animal results to human clinical trials.
- supports: Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®)… (Progress in retinal and eye research 2016) · cited 90x in the literature
"To date, long-term pharmacological studies in animal models of diabetes have demonstrated that the onset and development of ocular complications that include keratopathy, retinopathy and cataract can be ameliorated by the control of excess metabolic flux through aldose reductase (AR)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. (Diabetes 1985) · cited 79x in the literature
"Our results indicated that the aldose reductase inhibitor sorbinil, a spirohydantoin, arrested further progression and promoted a reparative process despite continuation of hyperglycemia and elevated lens glucose." (abstract, results, passage verified)
pubmedfull study (doi) - supports: NIH conference. Aldose reductase and complications of diabetes. (Annals of internal medicine 1984) · cited 168x in the literature
"Sorbitol, formed in the presence of aldose reductase, accumulates in the lens during hyperglycemia. Dulcitol similarly accumulates in the presence of galactosemia. Cataractogenesis in both cases can be prevented by inhibitors of aldose reductase." (abstract, results, passage verified)
pubmedfull study (doi)
Approximately 35% of all FDA-approved drugs (around 700 drugs) interact with G-protein coupled receptors (GPCRs).
"There are 700 FDA-approved drugs that interact with GPCRs. I think it's like 35% of all drugs involve GPCRs, and that's what our drug is doing." (said at 0:34:45)
Published pharmacological analyses and reviews of FDA databases confirm that approximately 34% to 35% of approved drugs target G protein-coupled receptors (GPCRs). Depending on how individual drug entities, salt forms, and combinations are counted across databases (such as ChEMBL, Guide to PHARMACOLOGY, and the FDA Orange Book), estimates of the total number of approved GPCR-targeting drugs range from roughly 475 to approximately 700.
Acetylcholine binding to the muscarinic receptor sends a negative signal that inhibits sensory neuron growth, and blocking this receptor with an antagonist removes this cholinergic constraint and increases nerve growth.
"what we've discovered is that the muscarinic receptor is a key component of a negative influence. So acetylcholine, which is a neurotransmitter, binds to the muscarinic receptor, sends a negative signal that inhibits growth. And we've done lots of studies to uncover all that. And so, when you come in with an antagonist or a blocker of the receptor, you block this cholinergic constraint, as we as we termed it, and you see increased growth." (said at 0:34:05)
Preclinical in vitro and animal studies demonstrate that endogenous acetylcholine acts via muscarinic acetylcholine type 1 receptors (M1R) to exert a tonic inhibitory effect ('cholinergic constraint') on adult sensory neuron neurite outgrowth and mitochondrial function. Genetic knockout of M1R or pharmacological blockade using selective M1R antagonists (such as pirenzepine or MT7) removes this inhibition and promotes sensory neuron growth and peripheral nerve regeneration.
Pirenzepine does not cross into the central nervous system.
"pirenzepine was one of those drugs that existed that did not cross into the CNS. So, it made it purely a peripheral acting drug." (said at 0:39:28)
Pirenzepine is a selective M1 muscarinic receptor antagonist that is hydrophilic and does not effectively cross the blood-brain barrier under standard systemic administration, making its pharmacological actions predominantly restricted to the peripheral nervous system and peripheral tissues. It is widely used in pharmacological and clinical research specifically as a peripherally restricted muscarinic antagonist to distinguish central from peripheral cholinergic effects.
- supports: Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic … (Archives of general psychiatry 2001) · cited 41x in the literature
"Twelve patients with PD received biperiden hydrochloride (a muscarinic antagonist that crosses the blood-brain barrier), pirenzepine hydrochloride (a muscarinic antagonist that does not cross the blood-brain barrier), or placebo 2 hours before a 35% carbon dioxide-65% oxygen respiratory challenge" (abstract, methods, passage verified)
pubmedfull study (doi) - supports: [Involvement of cholinergic mechanism in respiratory chemosensitivity to CO2 in humans]. (Nihon Kyobu Shikkan Gakkai zasshi 1992)
"Pirenzepine, a M1 muscarinic antagonist which does not cross the blood-brain barrier, biperiden, another M1 muscarinic antagonist which is expected to penetrate into the central nervous system, or placebo was intravenously preinjected before the measurement of ventilatory responses." (abstract, methods, passage verified)
pubmed - supports: Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acety… (Journal of Alzheimer's disease : JAD 2014) · cited 13x in the literature
"Inhibition of muscarinic AChR restricted to the periphery may present a therapeutic advantage as it avoids adverse central cholinergic effects." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Pirenzepine was developed by Boehringer Ingelheim as an oral drug for gastric ulcers that blocks acetylcholine-driven release of hydrochloric acid in the stomach.
"pirenzepine existed and it had been used in millions of people around the world um for treating gastric ulcers. Um it was developed by a a German company, Boehringer Ingelheim. Um and you took it as an oral um pill, I believe. And it blocked acetylcholine um driven release of HCl in the stomach." (said at 0:39:58)
Pirenzepine is a selective muscarinic M1 receptor antagonist originally developed by Boehringer Ingelheim (marketed under brand names including Gastrozepin) as an oral therapeutic for peptic and gastric ulcers. Pharmacologically, it inhibits acetylcholine-mediated stimulation of gastric acid (hydrochloric acid) secretion by blocking muscarinic receptors involved in cholinergic signaling in the gastrointestinal tract.
Corneal confocal microscopy can be used to image sensory nerves live and in real time in humans or animals to measure nerve degeneration and regeneration.
"There's also a very interesting technique called corneal confocal microscopy which takes a confocal microscope and aims it at the eye... And it has been well documented now by a colleague of ours, um Rayaz Malik, who's worked on this now and really elevated it to an art form as well as a science form, that you can use these corneal confocal microscopes to look at nerves in real time... So, you can use this to measure degeneration, apply drugs to the eye and look at regeneration, all in a human or an animal live." (said at 0:42:28)
Corneal confocal microscopy (CCM) is an established, non-invasive in vivo imaging technique used in humans and animal models to visualize sub-basal corneal nerve fibers in real time. Extensive research, notably led by Rayaz Malik and colleagues, demonstrates that CCM detects small sensory nerve fiber degeneration in neuropathies (such as diabetic peripheral neuropathy) and captures early nerve regeneration following therapeutic or surgical interventions.
Alzheimer's drugs that reduce brain beta-amyloid or inhibit beta-secretase do not preserve cognition compared to placebo.
"We've run into a very similar uh conundrum as it relates to Alzheimer's drugs. Uh, you know, they're the drugs are clearly shown to both uh rid the brain of beta-amyloid uh or work uh on its production via what's called beta-secretase to reduce its production. And do they do that? You bet they do. Uh, but they don't really have much effect on cognition in terms of preservation. The people taking the drugs still decline just about as rapidly as those in the placebo group." (said at 0:52:26)
Randomized clinical trials and systematic reviews confirm that targeting amyloid-β production or clearance yields minimal to no clinically meaningful preservation of cognition compared to placebo. Oral beta-secretase (BACE1) inhibitors successfully reduced amyloid-β production but failed to improve cognition, often causing slight early cognitive worsening. For amyloid-clearing monoclonal antibodies (such as aducanumab, lecanemab, and donanemab), systematic reviews and meta-analyses show that although some trials achieved statistically significant slowing of decline, the absolute effect on cognitive scales is very small (e.g., Cochrane meta-analysis finding a standardized mean difference of -0.11 on the ADAS-Cog scale), with patients in treatment groups continuing to experience progressive cognitive decline.
- supports: BACE Inhibitor Clinical Trials for Alzheimer's Disease. (Journal of Alzheimer's disease : JAD 2024) · cited 20x in the literature
"However, although effective in preventing amyloid-β production in late-stage clinical trials, BACE inhibitors have been associated with early, non-progressive, likely reversible, cognitive decline." (abstract, passage verified)
pubmedfull study (doi) - supports: Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or … (The Cochrane database of systematic reviews 2026) · cited 20x in the literature
"Compared to placebo, amyloid-beta-targeting monoclonal antibodies probably result in little to no difference in cognitive function as measured by the ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive) scale (standardised mean difference (SMD) -0.11, 95% confidence interval (CI) -0.16 to -0.06; 13 studies, 9895 participants; moderate certainty). Dementia severity Amyloid-beta-targeting monoclonal antibodies may result in little to no difference in dementia severity as measured by the CDR-SB (Clincal Dementia Rating Sum of Boxes) scale (SMD -0.12, 95% CI -0.24 to -0.00; 9 studies, 8053 participants; low certainty)." (abstract, results, passage verified)
pubmedfull study (doi)
Leprosy remains a leading cause of peripheral neuropathy worldwide.
"infectious disease can cause this type of nerve damage as well and leprosy still is present globally and one of the leading causes of neuropathy." (said at 1:02:10)
The speaker's statement that infectious diseases cause nerve damage and that leprosy remains present globally as a leading cause of peripheral neuropathy is supported by published literature. While rare in high-income countries, leprosy (caused by Mycobacterium leprae) continues to be recognized globally as one of the leading infectious and non-traumatic causes of peripheral neuropathy and associated physical disability.
There are five distinct subtypes of muscarinic acetylcholine receptors.
"It's relatively specific for a G protein coupled receptor called the muscarinic receptor. It's actually a type 1. There's actually five subtypes, so it's quite complex." (said at 0:32:45)
The claim is supported by established pharmacological and molecular biology literature. Muscarinic acetylcholine receptors are a family of five distinct G protein-coupled receptor subtypes designated M1 through M5.
High systemic doses of antimuscarinic medications commonly induce side effects such as dry mouth and tachycardia.
"When you have give too high doses systemically, you're going to start getting you know, the dry mouth, the tachycardias, the things that one associates with antimuscarinics in high doses." (said at 0:42:07)
The claim is supported by clinical literature. High systemic exposure or toxicity from antimuscarinic (parasympatholytic) agents classically produces peripheral anticholinergic manifestations, most notably dry mouth (xerostomia) and tachycardia.
- supports: Datura and Brugmansia plants related antimuscarinic toxicity: an analysis of poisoning cas… (Clinical toxicology (Philadelphia, Pa.) 2019) · cited 23x in the literature
"Most frequently observed clinical effect was mydriasis (53.2%), followed by confusion (40%), tachycardia (35.5%), dry mouth (35.5%), dizziness (34%), dry skin (32.5%), and delirium (31%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Mydriatic and cycloplegic drugs: a review of ocular and systemic complications. (American journal of optometry and physiological optics 1982) · cited 79x in the literature
"The systemic complications are those common to sympathomimetic and parasympatholytic drugs and include tachycardia, hypertension, headache, faintness. pallor, trembling, excessive sweating, palpitations, arrhythmias, confusion, hallucinations, drowsiness, ataxia, flushed skin, high fever, dysarthria, thirst, dry mouth, convulsions, disorientation, nervousness, coma, and death." (abstract, results, passage verified)
pubmed
Standard nerve conduction studies assess large-fiber nerve function rather than small-fiber nerve function.
"the nerve conduction studies are large fiber studies and a lot of the a lot of the problems that we've described in diabetic neuropathy are small fiber." (said at 0:50:25)
Standard nerve conduction studies evaluate myelinated, large-diameter A-alpha and A-beta nerve fibers and cannot record the activity of unmyelinated (C) or thinly myelinated (A-delta) small fibers. Because early or painful diabetic peripheral neuropathy frequently presents as small-fiber pathology, nerve conduction studies are often normal in these patients and require specialized modalities (such as skin biopsy to assess intraepidermal nerve fiber density, corneal confocal microscopy, or quantitative sensory testing) to detect small-fiber impairment.
Approximately 50% of people with diabetes develop neuropathy.
"if 50% of diabetics are going to have neuropathy, that becomes a big number." (said at 1:02:40)
The claim is supported by medical literature and clinical reviews on diabetic peripheral neuropathy. Diabetic peripheral neuropathy (DPN) is widely recognized as affecting up to 50% of people with diabetes mellitus over their lifetime (PMID: 42660716, PMID: 38967712, PMID: 37670573).
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.